These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 12480753)
1. Decreased cerebrospinal fluid levels of neurosin (KLK6), an aging-related protease, as a possible new risk factor for Alzheimer's disease. Mitsui S; Okui A; Uemura H; Mizuno T; Yamada T; Yamamura Y; Yamaguchi N Ann N Y Acad Sci; 2002 Nov; 977():216-23. PubMed ID: 12480753 [TBL] [Abstract][Full Text] [Related]
2. Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy. Wennström M; Surova Y; Hall S; Nilsson C; Minthon L; Boström F; Hansson O; Nielsen HM PLoS One; 2013; 8(1):e53250. PubMed ID: 23308173 [TBL] [Abstract][Full Text] [Related]
3. Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease. Ogawa K; Yamada T; Tsujioka Y; Taguchi J; Takahashi M; Tsuboi Y; Fujino Y; Nakajima M; Yamamoto T; Akatsu H; Mitsui S; Yamaguchi N Psychiatry Clin Neurosci; 2000 Aug; 54(4):419-26. PubMed ID: 10997858 [TBL] [Abstract][Full Text] [Related]
4. Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer's disease. Patra K; Soosaipillai A; Sando SB; Lauridsen C; Berge G; Møller I; Grøntvedt GR; Bråthen G; Begcevic I; Moussaud S; Minthon L; Hansson O; Diamandis EP; White LR; Nielsen HM Alzheimers Res Ther; 2018 Jan; 10(1):9. PubMed ID: 29378650 [TBL] [Abstract][Full Text] [Related]
5. Characterization of a brain-related serine protease, neurosin (human kaillikrein 6), in human cerebrospinal fluid. Okui A; Kominami K; Uemura H; Mitsui S; Yamaguchi N Neuroreport; 2001 May; 12(7):1345-50. PubMed ID: 11388408 [TBL] [Abstract][Full Text] [Related]
6. Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. Diamandis EP; Scorilas A; Kishi T; Blennow K; Luo LY; Soosaipillai A; Rademaker AW; Sjogren M Clin Biochem; 2004 Mar; 37(3):230-7. PubMed ID: 14972646 [TBL] [Abstract][Full Text] [Related]
7. Value of measuring plasmatic levels of neurosin in the diagnosis of Alzheimer's disease. Menendez-Gonzalez M; Castro-Santos P; Suarez A; Calatayud MT; Perez-Pinera P; Martinez M; Ribacoba R; Gutierrez C J Alzheimers Dis; 2008 May; 14(1):59-67. PubMed ID: 18525128 [TBL] [Abstract][Full Text] [Related]
8. Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies. Nielsen HM; Hall S; Surova Y; Nägga K; Nilsson C; Londos E; Minthon L; Hansson O; Wennström M J Alzheimers Dis; 2014; 40(2):343-50. PubMed ID: 24448788 [TBL] [Abstract][Full Text] [Related]
9. Extracellular neurosin degrades α-synuclein in cultured cells. Tatebe H; Watanabe Y; Kasai T; Mizuno T; Nakagawa M; Tanaka M; Tokuda T Neurosci Res; 2010 Aug; 67(4):341-6. PubMed ID: 20403393 [TBL] [Abstract][Full Text] [Related]
10. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Bennett DA; Schneider JA; Bienias JL; Evans DA; Wilson RS Neurology; 2005 Mar; 64(5):834-41. PubMed ID: 15753419 [TBL] [Abstract][Full Text] [Related]
12. Amyloid pathology influences aβ1-42 cerebrospinal fluid levels in dementia with lewy bodies. Slaets S; Le Bastard N; Theuns J; Sleegers K; Verstraeten A; De Leenheir E; Luyckx J; Martin JJ; Van Broeckhoven C; Engelborghs S J Alzheimers Dis; 2013; 35(1):137-46. PubMed ID: 23364139 [TBL] [Abstract][Full Text] [Related]
13. Role of kallikrein enzymes in the central nervous system. Yousef GM; Kishi T; Diamandis EP Clin Chim Acta; 2003 Mar; 329(1-2):1-8. PubMed ID: 12589961 [TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758 [TBL] [Abstract][Full Text] [Related]
15. Alzheimer's Disease-Associated Cerebrospinal Fluid (CSF) Biomarkers do not Correlate with CSF Volumes or CSF Production Rate. Edsbagge M; Andreasson U; Ambarki K; Wikkelsø C; Eklund A; Blennow K; Zetterberg H; Tullberg M J Alzheimers Dis; 2017; 58(3):821-828. PubMed ID: 28505972 [TBL] [Abstract][Full Text] [Related]
16. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042 [TBL] [Abstract][Full Text] [Related]
17. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia. Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675 [TBL] [Abstract][Full Text] [Related]
18. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies. Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322 [TBL] [Abstract][Full Text] [Related]